By IDSE News Staff
Positive results from ZeNix, a phase 3 trial seeking to improve a key treatment strategy for highly drug-resistant tuberculosis, could lead to changes in TB treatment guidelines and have real benefits for people living with TB, according to a presentation made at the International AIDS Society (IAS) 2021 conference, which was held virtually.
The ZeNix study (ClincalTrials.gov Identifier: NCT03086486) enrolled 181 people with highly drug-resistant TB in South Africa,